Cardinal Health’s sell-off was an overreaction. We’d be buyers
We’ve taken a closer look at Cardinal Health’s quarterly results and conference call following Thursday’s sell-off. Our conclusion:…
The money to AI stocks is a problem, and how it can be fixed
We do not have enough money coming into this market. The funds flow only to stocks tied to…
Here’s a rapid-fire update on all our AI stocks and 5 names Jim Cramer wants to buy
On Friday, the CNBC Investing Club held its March Monthly Meeting, where Jim Cramer and Director of Portfolio…
We’re dipping into our large cash pile to buy more of this health-care stock
We are buying 90 shares of Cardinal Health at roughly $217. Following the trade, Jim Cramer’s Charitable Trust…
We’re initiating a position in this health-care stock with a $260 price target
Shortly after the opening bell, we will initiate a position in Cardinal Health , buying 170 shares at…
We’re adding a stock to our Bullpen; resistant to recessions, AI disruption
We added a new Bullpen name during Friday’s Monthly Meeting, and it has minimal economic sensitivity and faces…
More drugs should be over-the-counter
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter”…
I talked to many health CEOs out West and see big things for drug stocks
We get so caught up in the buzz and the sizzle that we forget about the steak, especially…